List view / Grid view
23 February 2015 | By Eli Lilly & Company
Eli Lilly and Company announced a delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015...
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response…
19 February 2015 | By Eli Lilly and Company
Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months...
11 February 2015 | By Eli Lilly & Company
College freshmen face tremendous pressure, often trying to adjust to tough academic standards while living away from home for the first time...
9 February 2015 | By Eli Lilly and Company
Eli Lilly and Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST...
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
3 February 2015 | By Lilly Diabetes
Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships...
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
14 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299)...
17 December 2014 | By Eli Lilly and Company
Eli Lilly and Company has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA(R) (ramucirumab)...
9 December 2014 | By Eli Lilly and Company
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…
30 October 2014 | By Eli Lilly and Company
Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...
29 October 2014 | By Eli Lilly and Company
Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...
